25 completed, 10 active not recruiting, 3 recruiting, 3 terminated. 43 Phase 3, 4 Phase 2.
By phase and status
Follow Sweat Gland Diseases: new trials by email Literature Review of Sweat Gland Diseases trials Research Report on Sweat Gland Diseases
Trials (filtered) newest first · largest first
All 43 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
Remibrutinib - Hidradenitis Suppurativa | Phase 3 | Recruiting | 710 | 2026-07-10 | 2026-10-13 |
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
BFB759, Placebo for BFB759 - Hidradenitis Suppurativa (HS) | Phase 2 / Phase 3 | Active not recruiting | 210 | 2025-11-03 | 2026-10-14 |
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
Sonelokimab - Hidradenitis Suppurativa | Phase 3 | Enrolling by invitation | 835 | 2025-06-27 | 2026-06-08 |
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
Ruxolitinib Cream, Vehicle Cream - Hidradenitis Suppurativa | Phase 3 | Active not recruiting | 580 | 2025-06-23 | 2026-07-28 |
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
Ruxolitinib Cream, Vehicle Cream - Hidradenitis Suppurativa | Phase 3 | Active not recruiting | 573 | 2025-06-12 | 2026-07-08 |
Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients
ROCEPHIN, metronidazole, RIFADIN, IZILOX, placebo combination therapy, Lymecyclin and corresponding placebos of the experimental arm - Hidradenitis Suppurativa | Phase 3 | Recruiting | 92 | 2025-05-22 | 2025-07-09 |
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
Bimekizumab - Hidradenitis Suppurativa | Phase 3 | Active not recruiting | 43 | 2025-04-07 | 2026-09-25 |
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1 - Hidradenitis Suppurativa | Phase 3 | Active not recruiting | 565 | 2025-03-20 | 2026-10-15 |
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
povorcitinib - Hidradenitis Suppurativa (HS) | Phase 3 | Recruiting | 600 | 2025-02-28 | 2026-10-30 |
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1 - Hidradenitis Suppurativa | Phase 3 | Active not recruiting | 588 | 2025-01-31 | 2026-10-15 |
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
Sonelokimab - Hidradenitis Suppurativa | Phase 3 | Active not recruiting | 35 | 2024-12-30 | 2026-05-06 |
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Lutikizumab, Placebo - Hidradenitis Suppurativa | Phase 3 | Active not recruiting | 1400 | 2024-06-27 | 2026-09-02 |
A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Sonelokimab, Placebo - Hidradenitis Suppurativa | Phase 3 | Completed | 422 | 2024-05-15 | 2026-08-12 |
Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Sonelokimab, Placebo - Hidradenitis Suppurativa | Phase 3 | Completed | 418 | 2024-05-14 | 2026-06-08 |
A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab
Spesolimab, Placebo - Hidradenitis Suppurativa (HS) | Phase 2 / Phase 3 | Terminated | 39 | 2024-05-08 | 2026-06-17 |
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
Povorcitinib - Hidradenitis Suppurativa (HS) | Phase 3 | Active not recruiting | 617 | 2024-01-30 | 2026-08-25 |
Hidradenitis Suppurativa Study of Izokibep
Placebo, Izokibep - Hidradenitis Suppurativa | Phase 3 | Terminated | 258 | 2023-06-22 | 2025-10-15 |
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
Upadacitinib, Placebo - Hidradenitis Suppurativa | Phase 3 | Active not recruiting | 1328 | 2023-06-21 | 2026-08-20 |
Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa
Spesolimab i.v., Spesolimab s.c., Placebo matching Spesolimab i.v. - Hidradenitis Suppurativa | Phase 2 / Phase 3 | Completed | 209 | 2023-04-17 | 2025-11-05 |
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
Povorcitinib, Placebo - Hidradenitis Suppurativa (HS) | Phase 3 | Completed | 619 | 2023-02-22 | 2026-01-09 |
Showing 20 of 43. Sign in to see all of them.
Narrower conditions
Hidradenitis Suppurativa (33) · Hidradenitis (10) · Hyperhidrosis (10) · Skin Diseases (7) · Skin Diseases, Bacterial (4) · Suppuration (4) · Acne Vulgaris (3) · Dermatitis (2) · Furunculosis (2) · Psoriasis (2) · Abscess (1)
Broader conditions
Skin and Connective Tissue Diseases (43) · Skin Diseases (36) · Bacterial Infections (33) · Bacterial Infections and Mycoses (33) · Infections (33) · Skin Diseases, Infectious (33) · Skin Diseases, Bacterial (29) · Suppuration (29) · Hidradenitis (23) · Inflammation (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Acneiform Eruptions (3) · Sebaceous Gland Diseases (3)
Interventions
Adalimumab (4) · bimekizumab (4) · sonelokimab (4) · remibrutinib (3) · secukinumab (3) · Botulinum Toxins, Type A (2) · oxybutynin (2) · Aluminum Chloride (1) · Ceftriaxone (1) · Cosmetics (1) · Laser Therapy (1) · Metformin (1) · Metronidazole (1) · Moxifloxacin (1) · Rifampin (1)
Sponsors
Incyte Corporation (6) · Novartis Pharmaceuticals (6) · MoonLake Immunotherapeutics AG (4) · UCB Biopharma SRL (4) · AbbVie (3) · AbbVie (prior sponsor, Abbott) (3) · Journey Medical Corporation (3) · Boehringer Ingelheim (2) · ACELYRIN Inc. (1) · Allergan (1) · Bluefin Biomedicine, Inc. (1) · Cristália Produtos Químicos Farmacêuticos Ltda. (1) · Direction Centrale du Service de Santé des Armées (1) · Dr. August Wolff GmbH & Co. KG Arzneimittel (1) · GlaxoSmithKline (1)
Countries
United States (30) · Germany (28) · Canada (24) · France (24) · Spain (23) · Poland (22) · Bulgaria (19) · Belgium (15) · Czechia (15) · Italy (15) · Australia (14) · Netherlands (14) · United Kingdom (14) · Greece (13) · Japan (13)
Top investigators
Lynne M Deans, MT (2) · Prof Kristian Reich, M.D., Ph.D. (equ.) (2) · Daniel Eisen, M.D. (1) · David Williams, MD (1) · Finn Gottrup, DMsci (1) · Lynne Deans, MT (1)
Results publications
PMID 31111409, PMID 41248770, PMID 42482599, PMID 42525209, PMID 27518661, PMID 29380251, PMID 30378087, PMID 32147881, PMID 36746171, PMID 38795716, PMID 39101698, PMID 39141589, PMID 39425517, PMID 40153232, PMID 40172122, PMID 40372667, PMID 40652434, PMID 40839197, PMID 41107641, PMID 41689425, PMID 42247110, PMID 42493571, PMID 26114588, PMID 37280417, PMID 39611771, PMID 40524676
NIH funding
2023 (5), 2015 (2), 2018 (2), 2019 (2), 2014 (1), 2025 (1)